ADAR1 Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

ADAR1 Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.82M	Buy	143,199 +52,600	+58%	+$1.81M	0.27%	87
2026 Q1	$2.85M	Sell	90,599 -400	-0.4%	-$11.5K	0.17%	110
2025 Q4	$2.26M	Buy	90,999 +50,999	+127%	+$1.02M	0.17%	95
2025 Q3	$649K	Hold	40,000	–	–	0.06%	123
2025 Q2	$524K	Buy	40,000 +20,000	+100%	+$288K	0.08%	115
2025 Q1	$440K	Buy	+20,000	New	+$525K	0.08%	113
2024 Q4	–	Sell	-18,178	Closed	-$485K	–	244
2024 Q3	$485K	Sell	18,178 -418,430	-96%	-$8.32M	0.08%	119
2024 Q2	$7.86M	Buy	436,608 +255,697	+141%	+$4.46M	1.48%	15
2024 Q1	$3.3M	Buy	+180,911	New	+$2.88M	0.75%	24

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ADAR1 Capital Management's EWTX Position: Q2 2026 in Review

ADAR1 Capital Management increased its Edgewise Therapeutics (EWTX) stake by 58% in Q2 2026, buying an estimated $1.81M and bringing the position to 143,199 shares worth $5.82M. The position accounts for 0.27% of the portfolio, ranked #87.

ADAR1 Capital Management first reported a position in EWTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $7.86M in Q2 2024. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

ADAR1 Capital Management held 143,199 shares of Edgewise Therapeutics worth $5.82M as of Q2 2026.
ADAR1 Capital Management bought 52,600 Edgewise Therapeutics shares in Q2 2026, an estimated $1.81M.
Edgewise Therapeutics made up 0.27% of ADAR1 Capital Management's portfolio in Q2 2026, its #87 holding.
ADAR1 Capital Management first reported a position in Edgewise Therapeutics in Q1 2024 and has held it in 9 quarters since.
ADAR1 Capital Management's Edgewise Therapeutics position peaked at $7.86M in Q2 2024.
226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.